ʻO Hypolipidemic agent Tricor: nā ʻōlelo no ka hoʻohana ʻana, nā kumukūʻai, nā loiloi a me nā analogues o ka lāʻau lapaʻau

Pin
Send
Share
Send

Nā papa Oral ʻO Tricor ʻelua o 145 a me 160 mg nā mea manamana i ke ʻano o ka fenofibrate.

Aʻo ka hana o ka lāʻau lapaʻau, ka lipid-hina i lalo (a i ʻole e hoʻohaʻahaʻa i ka neʻe o nā lipids). Aia ka lāʻau lapaʻau i ka hui pharmacological o fibrates.

ʻO keʻano maʻamau

Kūkulu, ua hoʻohana ʻia ka lāʻau lapaʻau no nā ala e pili i:

  • me nā holomua kūlike o ka insulin a me ka ole-insulin e hilinaʻi nei i ka maʻi diabetes mellitus;
  • me ka hypercholesterolemia (kiʻekiʻe kolamu ma ke koko), hyperglyceridemia (nui triglycerides);
  • me ka hyperlipidemia i hui ʻia (nā kiʻekiʻe koko o nā kolamu a me nā momona, a me ka triglyceride);
  • a me kēlā me nā hyperlipidemia ʻē aʻe.
E pili ana i ka hyperlipidemia, hiki iā mākou ke ʻōlelo ʻo ia ke kūʻē nui i ka naʻau a me nā moku koko a me ke kumu nui o ka make, no ka laʻana, i kahi ʻāina e like me ka United States.

ʻO ka ʻike no ka lālā ʻo Tricor ma kahi hui haukapila a me ka lāʻau lapaʻau lāʻau, aʻo nā mea hana i ʻōlelo iā Recipharm Monts, a me Laboratoies Fournier S.A. he lue wale ia.

Ke hana lāʻau lapaʻau a me nā hōʻike

I ka wā o ka hoʻāʻo ʻana i ka lāʻau lapaʻau Tricor pololei i loko o nā kauka, ua hōʻike ʻia nā haʻawina i nā mea maʻi me ke kōkua o fenofibrate, ua hoʻemi ʻia ka nui o ka kolamu ma ka poʻe maʻi ma o 20, a i ʻole 25%, a me ka manaʻo e hoʻohaʻahaʻa i kā lākou triglycerides, aia kēia hōʻailona ma ka nūnū 40 a i 55%.

Nā Puʻuwai Tricor 145 mg

Eia kekahi, i nā mea maʻi me ka hypercholesterolemia, ka palena o ka nui a me ka LDL cholesterol i emi iho. Pono e noʻonoʻo ʻia ua lilo kēia kuʻina o kekahi o nā mea i hoʻoholo i ka nui o ka ulu ʻana o ka maʻi naʻau coronary.

Ka lāʻau hōʻike ʻia kahi hana hoʻoneʻe i ka mālama ʻana i ka lāʻau lapaʻau. I kēlā me kēia ʻano hoʻoikaika kino pilikino, nā ʻano o ke kaupaona ʻana, a me ka hoʻohana ʻana i kahi ʻai no nā maʻi.

  • hypertriglycemia koʻikoʻi;
  • hui pū ʻia ka hyperlipidemia, inā loaʻa nā contraindications no nā statins (nā lāʻau lapaʻau e hoʻohaʻahaʻa i ka kolesterol ma ke koko);
  • huiʻāina hyperlipidimia. I ka nui o ka maʻi o ka maʻi āpau o nā maʻi cardiac a me vascular;
  • a ua ʻōlelo ʻia nā papa i mua o ka maʻi mellitus o ka maʻi i ka wā o ka pāʻai a me ke ʻano hana kino ʻaʻole pono.

Hoʻolaha hopena

ʻO Fenofibrate kahi mea i loaʻa mai ka momona fibric. Hoʻololi ia i ka hoʻohālikelike o nā lipids i ke koko.

I ka wā mālama, ua ʻike ʻia nā loli like:

  • hoʻonui hoʻomaʻemaʻe a hoʻomaʻemaʻe paha;
  • i nā mea maʻi me ka loaʻa ʻana o ka maʻi puʻuwai coronary, hoʻemi ka pae o ka lipoproteins atherogenic (ratio, e hoʻonui ana i ka hopena o ka atherosclerosis) a i ʻole ka "kino" kolesterol;
  • hoʻonui i ka hoʻonui ʻana i ka cholesterol "maikaʻi";
  • ka hiki ke hōʻemi i ka waihona intravascular;
  • ka emi ka pae o ka fibriogen;
  • ke hoʻokaʻawale nei ke koko i ka ʻike o ka uric acid, a me ka hana C-reactive hana i loko o kāna plasma.

ʻO ka nui o ka kiko o ka fenofibrate i loko o ke koko e loaʻa i loko o kahi mau hola ma hope o ka lawe ʻana i ka Tricor mea maʻi.

ʻOiai i nā hihia o ka hoʻokō lōʻihi me kahi lāʻau lapaʻau, ʻaʻole kēia ke alakaʻi i ka hōʻiliʻili o ke kino.

Hoʻopiha piha ia i loko o nā lā 6-7 mau lā i ka nui me ka urine. I ka manawa like, ʻaʻole excreted i ka fenofibrate i ka wā o hemodialysis, no ka mea ʻike ʻia a paʻa mau i nā plasma albumin (ka nui ka protein).

Nā Hoʻohui

ʻO ka papa inoa o nā contraindications i ʻike ʻia ma ke kaʻina noiʻi, a me ka hopena o ka hana ma ka hoʻohana ʻana iā Treycor, penei:

  • ke kiʻekiʻe o ka maʻa o ka kino e fenofibrate, a me nā meaʻokoʻa'ē aʻe o ka lāʻau;
  • hepatic, renal failed;
  • cirrhosis o ka ate;
  • mau makahiki malalo mai o 18 makahiki;
  • photosensitivity (hoʻonui i ka naʻau o ka membrane me ka ʻili o nā ʻāpana ultraviolet a ʻike ʻia i ka ʻike kikoʻī maka radiation), a me ka phototoxicity;
  • maʻi ōpū;
  • kahi hōʻike o kahi alerine i nā huinā a me kāna mau ʻaila, i nā huahana soy, kahi i hōʻike ʻia i loko o ke kaʻina o ka hōʻiliʻili anamnesis a i ʻole ninaninau i kahi mea maʻi ma mua o ke kau ʻana i kahi lāʻau lapaʻau;
  • lactation.

Me ka mālama aka, ua kuhikuhi ʻia ʻo Tricor i ka wā i hoʻomanawanui:

  • hōʻino maikaʻiʻole i ka waiʻona;
  • e pili ana i ka hypothyroidism a i ʻole ka hemahema o nā hormones thyroid;
  • i ka elemakule;
  • mau mai nā maʻi ʻōiwi.

Kahawai

ʻO kēia ka ʻike e pili ana i nā hoʻokolohua lapaʻau a me ke kaʻina o ka hoʻohana ʻana i ka lāʻau lapaʻau e nā wahine hāpai, ʻaʻole lawa.

No ka laʻana, i loko o nā hoʻokolohua me nā holoholona, ​​ʻaʻole i ʻike ʻia ka hopena tetratogenic (hoʻomohukū a me ka hoʻomoholo ʻia ma lalo o ka mana o ka lāʻau).

Eia kekahi, ma ke kaʻina o nā hoʻokolokolo preclinical, ua hōʻike ʻia ka embryotoxicity ma muli o ka hoʻohana o kekahi o nā wahine hāpai i ka nui o ka lāʻau. Eia naʻe, ʻaʻole i hoʻoholo ʻia ka hopena no ka wahine hāpai.

Pono ka lāʻau lapaʻau ʻo Tricor e kuhikuhi i nā wahine hāpai ma hope o ka loiloi ʻana i nā pono āpau a me nā pilikia paha.

Nā puka a me nā palapala

Lawe ʻia ka lāʻau ma ke alo, ke holoi ʻana i ka papa me ka wai. Ke paʻa ʻole ka manawa intake a ʻaʻole ia e hilinaʻi ma ka ʻai (Tricor 145). Pono ka ʻĀina o Tricorr 160 e hana i ka manawa like me ka meaʻai.

ʻO ka lā maʻi no nā maʻi he 1 papa i kēlā me kēia lā.

Eia kekahi, inā ua lawe mua nā mea maʻi i kahi papa o 160 milligrams o Tricor, a laila hiki iā lākou, inā pono, e hoʻololi e lawe i nā 145 milligrams o ka lāʻau lapaʻau, me kaʻole o ka hoʻoponopono ʻana o ka dosis. Pono ka poʻe maʻi i nā makahiki kahiko e lawe i kahi mahele maʻamau - ʻaʻole iʻoi aku ma mua o 1 papa i hoʻokahi lā i hoʻokahi manawa.

Ua ʻike ʻia ka hopena o ka lāʻau i nā maʻi o nā pōpoki a me ke aʻa. Kūʻē hoʻi nā loiloi ma kēia hihia. No laila, pono e lawe ʻia ʻo Taykor e nā mea maʻi me ka mālama ʻē loa.

ʻO ka lāʻau lapaʻau he manawa lōʻihi o ka hoʻohana ʻana, ʻoiai pono ʻoe e pili i ka meaʻai i kau mua ʻia. ʻO ka loiloi o ka hopena o ke ʻano o Tricoror therapy e lawe wale ʻia e ke kauka komo i ka wā e loiloi ai i ka ʻike o nā lipids ʻelua (nā momona a me nā mea like i like me ia), a me LDL, ka nui o ka kolamu, a me nā mea e pili ana i ka triglycerides.

I ka hihia no nā mau mahina ʻaʻole ʻike ʻia ka hopena o ka hopena, a laila pono e noʻonoʻo pono nā koho lapaʻau hou aku.

Nā Hoʻohui Kūʻai

Hoʻonui ʻo Fenofibrate i ka wā i hoʻohana ʻia me nā anticoagulants waha (nā lāʻau lapaʻau e hoʻopau ana i ka thrombosis) e hoʻonui i ka hopena o ka hopena a hiki i ka nui o ke kahe i ke kahe, ʻo ia nā mea i hoʻoneʻe ʻia nā lāʻau antithrombotic i nā pūnaewele e hoʻoneʻe ʻia ana e ka protein i hoʻopaʻa ʻia i ka plasma koko.

No laila, i ka hoʻomaka ʻana o ka hopena me ka fenofibrate, pono e hōʻemi i ka ʻai ʻana i kēlā mau lāʻau lapaʻau e ka hapakolu a ma hope e koho lohi ʻia i kahi momona kūpono e like me ka pae INR (paeʻāina kūhelu ʻoihana maʻamau). E like me ka hoʻohana pū ʻana me kahi lāʻau lapaʻau e like me ka cyclosporine, aia ma loko o ke ʻano he nui nā hopena koʻikoʻi o kona hopena me ka fenofibrate.

Akā inā pono kēia, a laila pono e nānā i nā hana o ka pūpū, a laila ʻike hou nā loli hou i kāna mau ʻōnaehana, e wehe koke iā Tricor. ʻO nā mea maʻi e ʻike ʻia i ka hyperlipodemia, lawe i nā lāʻau lāʻau hormonal a i ʻole paha i ʻike nā mea ʻawaʻī e pono ke ʻike i ke ʻano o kēia ʻano kuʻuna, no ka mea, he ʻona a me ke ʻano ʻelua.

ʻO ka maʻi o ka lua o nā maʻi, hiki ke hoʻāla ʻia e ka estrogen intake, i kekahi mau mea i hōʻoia ʻia e kekahi anamnesis a nīnau paha i nā mea maʻi.

ʻO kekahi manawa, i ka hoʻohanaʻana o Tricor me kekahi mau lāʻau lapaʻau, he piʻi i ka transaminase (he mau enzim kēia i loko o ka puna e hoʻoneʻe i nā molika waikawa amino) ʻike ʻia i ka ate.

I ka manawa like, aia kahi wehewehe o nā hoʻopiʻi e pili ana me ka lawe ʻana i Tricor i ke ʻano o ka pancreatitis. Ua pili kēia mau kaʻina hana a me ka hopena pololei o ka lāʻau, a me ka neʻe ʻana o nā pōhaku a i ʻole ka hoʻokumu ʻana i ka sediment i ke ʻano o nā ʻano paʻa ma ka palahalaha, e hoʻopiʻi ana i ka hana maʻamau o ka bile dile.

ʻO ka poʻe maʻi e predisposed i ka myopathy (meʻa nā mākala kaunilo), a me ka poʻe i ʻoi aku ma mua o 70, mau nō hoʻi nā hōʻike o ka rhabdomyolysis (ke ala o ka luku ʻia o nā ʻāpau o ka iwi) ma muli o nā hopena o ka fenofibrate.

I nā kūlana a pau o ke olakino maikaʻi, pono ʻoe e hoʻokaʻawale i ka lawe ʻana iā Tricor.

Hoʻokumu ʻia ke kumu o ka lāʻau lapaʻau inā ka ʻoi aʻe o ka hopena o ka lapaʻau i ʻoi aʻe ma mua o nā hopena e hiki ai a me nā hopena o ka rhabdomyolysis.

Kūʻai a me nā hoʻohālikelike

ʻO ke kumukūʻai o Tricor i loko o nā halihali hiki mai ka 500 a hiki i 850 rubles, e like me nā kiʻekiʻe, (145 a 160 mg) nā hoʻohālikelike, me nā mea hana. Eia hou, he loli maoli ka uku maoli mai nā kumukūʻai i hōʻike ʻia ma nā pūnaewele lapaʻau.

E like me nā analogue o Tricor, nā lāʻau lapaʻau e like me:

  • Hōkohoke
  • Lipofem;
  • Lipicard
  • Lipanorm.

ʻOi aku ka nui o lākou ma mua o Tricor, aia ko lākou mau papa inoa o nā contraindications, a me ka ʻimi, pono nō e hoʻoholo e ke kauka. ʻAʻole ʻae ʻia kā lākou hoʻohana kūʻokoʻa.

Tricor: nā manaʻo manaʻo

Loaʻa nā loiloi ma ka lāʻau lapaʻau Tricor:

  • Yuri, Lipetsk, 46 makahiki. ^ E Ha yM. A no ke kōkō, ʻaʻole i hōʻemi ia, a hakakā maikaʻi ʻo Tricor me ka kolamu. Eia naʻe, pono e mālama ʻia i ke hoʻohana ʻana me ke koi ʻana o ka meaola;
  • ʻO Elena, Belgorod, he 38 makahiki. ^ E Ha yM. Ua hoʻomaikaʻi ke kūlana nui. Ua lawe wau i nā lāʻau lapaʻau no kahi mahina i kēia manawa, me he mea lā ua nalo wau. Ma hope koke, i ka koi ʻana o ke kauka, e hoʻāʻo ʻia au. Ke helu nei au i kahi manawa i ʻekolu mahina.
  • Boris, Moscow, 55 makahiki. ^ E Ha yM. Inu wau i ka Tricor lāʻau lapaʻau i nā papa o 3 mau mahina. ʻO ka ʻoi loa i kaʻu hihia e hoʻohaʻahaʻa i nā triglycerides.

Nā wikiō pili

ʻO nā mea āpau e pono ai ʻoe e ʻike e pili ana iā Tricor i ke wikiō.

Pin
Send
Share
Send